MA50864A - Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques - Google Patents
Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiquesInfo
- Publication number
- MA50864A MA50864A MA050864A MA50864A MA50864A MA 50864 A MA50864 A MA 50864A MA 050864 A MA050864 A MA 050864A MA 50864 A MA50864 A MA 50864A MA 50864 A MA50864 A MA 50864A
- Authority
- MA
- Morocco
- Prior art keywords
- acetylcystein
- urea
- treatment
- formulation based
- dermatological disorders
- Prior art date
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT201700125963 | 2017-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50864A true MA50864A (fr) | 2020-09-16 |
Family
ID=61527092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050864A MA50864A (fr) | 2017-11-06 | 2018-10-29 | Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210052524A1 (fr) |
EP (1) | EP3706714B1 (fr) |
ES (1) | ES2932359T3 (fr) |
MA (1) | MA50864A (fr) |
WO (1) | WO2019086366A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP2100456A1 (hu) * | 2021-12-28 | 2023-08-28 | Semmelweis Egyetem | Szemcsepp készítmény |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733535A (en) | 1995-10-25 | 1998-03-31 | The Procter & Gamble Co. | Topical compositions containing N-acetylcysteine and odor masking materials |
US6149925A (en) * | 1998-11-05 | 2000-11-21 | Color Access, Inc. | Topical compositions for enhancing glutathione production |
US20030229141A1 (en) | 1999-01-08 | 2003-12-11 | Yu Ruey J. | N-acetyl cysteine and its topical use |
US20030138466A1 (en) * | 2001-11-28 | 2003-07-24 | Bradley Pharmaceuticals, Inc. | Antioxidant dermatological composition |
CN100456932C (zh) * | 2002-08-20 | 2009-02-04 | 隆萨股份有限公司 | 游离甲醛低的稳定的醛供体和脱氢乙酸的增效抗菌组合物 |
US7556819B1 (en) * | 2003-07-25 | 2009-07-07 | Opi Products, Inc. | Skin composition |
US20110044920A1 (en) * | 2009-08-07 | 2011-02-24 | Mary Kay Inc. | Topical skin care formulations |
EP2397125A1 (fr) | 2010-06-15 | 2011-12-21 | Histocell, S.L. | Composition antioxydante |
US20150133472A1 (en) * | 2012-05-11 | 2015-05-14 | Cipla Limited | Pharmaceutical composition |
CN104225583B (zh) * | 2014-09-03 | 2016-09-28 | 苏州瑞派尔生物科技有限公司 | 一种用于皮肤损伤修复的组合物 |
US20160338993A1 (en) | 2015-05-21 | 2016-11-24 | The Regents Of The University Of California | Wound healing |
-
2018
- 2018-10-29 MA MA050864A patent/MA50864A/fr unknown
- 2018-10-29 EP EP18795526.5A patent/EP3706714B1/fr active Active
- 2018-10-29 ES ES18795526T patent/ES2932359T3/es active Active
- 2018-10-29 WO PCT/EP2018/079535 patent/WO2019086366A1/fr unknown
- 2018-10-29 US US16/967,265 patent/US20210052524A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2932359T3 (es) | 2023-01-18 |
US20210052524A1 (en) | 2021-02-25 |
EP3706714A1 (fr) | 2020-09-16 |
EP3706714B1 (fr) | 2022-09-14 |
WO2019086366A1 (fr) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50417A (fr) | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang | |
MA50786A (fr) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques | |
MA46052A (fr) | Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques | |
IL255203B (en) | Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders | |
MA42819A (fr) | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae | |
MA56387A (fr) | Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf | |
MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
MA49069A (fr) | Procédés et compositions pour le traitement d'apnée du sommeil | |
MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
MA50155A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale | |
MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
DK3405215T3 (da) | Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser | |
MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
MA47074A (fr) | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires | |
MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
MA49524A (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
IL269400A (en) | Medicines and preparations for the treatment of eye disorders | |
MA49794A (fr) | Composition utilisée dans le traitement prophylactique et thérapeutique de troubles de l'appareil cardiovasculaire | |
MA45668A (fr) | Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation |